[go: up one dir, main page]

DE69739792D1 - Verfahren zur Behandlung von Augenerkrankungen - Google Patents

Verfahren zur Behandlung von Augenerkrankungen

Info

Publication number
DE69739792D1
DE69739792D1 DE69739792T DE69739792T DE69739792D1 DE 69739792 D1 DE69739792 D1 DE 69739792D1 DE 69739792 T DE69739792 T DE 69739792T DE 69739792 T DE69739792 T DE 69739792T DE 69739792 D1 DE69739792 D1 DE 69739792D1
Authority
DE
Germany
Prior art keywords
treatment
eye diseases
image
eye
periocularly
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69739792T
Other languages
English (en)
Inventor
Peter D Spear
Joseph P Hammang
Edward E Baetge
William G Tsiaras
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Neurotech USA Inc
Original Assignee
Neurotech USA Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Neurotech USA Inc filed Critical Neurotech USA Inc
Application granted granted Critical
Publication of DE69739792D1 publication Critical patent/DE69739792D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F9/00—Methods or devices for treatment of the eyes; Devices for putting in contact-lenses; Devices to correct squinting; Apparatus to guide the blind; Protective devices for the eyes, carried on the body or in the hand
    • A61F9/0008—Introducing ophthalmic products into the ocular cavity or retaining products therein
    • A61F9/0017—Introducing ophthalmic products into the ocular cavity or retaining products therein implantable in, or in contact with, the eye, e.g. ocular inserts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A61K9/0051—Ocular inserts, ocular implants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K2035/126—Immunoprotecting barriers, e.g. jackets, diffusion chambers
    • A61K2035/128—Immunoprotecting barriers, e.g. jackets, diffusion chambers capsules, e.g. microcapsules

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Ophthalmology & Optometry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Vascular Medicine (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Emergency Medicine (AREA)
  • Obesity (AREA)
  • Cardiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
DE69739792T 1996-03-22 1997-03-24 Verfahren zur Behandlung von Augenerkrankungen Expired - Lifetime DE69739792D1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US08/620,982 US5904144A (en) 1996-03-22 1996-03-22 Method for treating ophthalmic diseases

Publications (1)

Publication Number Publication Date
DE69739792D1 true DE69739792D1 (de) 2010-04-15

Family

ID=24488233

Family Applications (2)

Application Number Title Priority Date Filing Date
DE69733357T Expired - Lifetime DE69733357T2 (de) 1996-03-22 1997-03-24 Apparat und verfahren zur behandlung von augenerkrankungen
DE69739792T Expired - Lifetime DE69739792D1 (de) 1996-03-22 1997-03-24 Verfahren zur Behandlung von Augenerkrankungen

Family Applications Before (1)

Application Number Title Priority Date Filing Date
DE69733357T Expired - Lifetime DE69733357T2 (de) 1996-03-22 1997-03-24 Apparat und verfahren zur behandlung von augenerkrankungen

Country Status (10)

Country Link
US (1) US5904144A (de)
EP (2) EP1574209B1 (de)
JP (3) JP2000507854A (de)
AT (2) ATE459335T1 (de)
AU (1) AU716400B2 (de)
CA (1) CA2264895C (de)
DE (2) DE69733357T2 (de)
DK (2) DK0927024T3 (de)
ES (2) ES2242223T3 (de)
WO (1) WO1997034586A2 (de)

Families Citing this family (103)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6299895B1 (en) * 1997-03-24 2001-10-09 Neurotech S.A. Device and method for treating ophthalmic diseases
KR100514277B1 (ko) 1996-09-13 2005-09-13 유겐가이샤 사이센딴이가꾸겡꾸쇼 신경 영양 인자의 안과용 조성물, 시신경 기능 장애 치료제 및 시신경 기능 장애 치료 방법
DE19718826A1 (de) * 1997-05-05 1998-11-12 Marion S Dr Eckmiller Verwendung biologisch aktiver Wirkstoffe zum Beeinflussen des Extrazellulär-Raumes von Sinneszellen und Verfahren zur Wirkstoff-Administrationssteuerung
WO1999013868A1 (en) * 1997-09-17 1999-03-25 Alcon Laboratories, Inc. Methods for treating ocular diseases
US7282482B2 (en) * 1998-04-08 2007-10-16 The Regents Of The University Of California NGF for the prevention of demyelination in the nervous system
EP1154691A4 (de) * 1999-01-05 2004-07-07 Massachusetts Eye & Ear Infirm Gezielte transsklerale gesteuerte wirkstoffabgabe an die retina und choroidae
US20070071734A1 (en) * 1999-04-06 2007-03-29 Weng Tao ARPE-19 as platform cell line for encapsulated cell-based delivery
US6361771B1 (en) 1999-04-06 2002-03-26 Neurotech S.A. ARPE-19 as a platform cell line for encapsulated cell-based delivery
EP1179061B1 (de) * 1999-05-07 2006-09-20 THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES Verfahren zur behandlung von tumoren mittels antiangiogener substanzen
US7943162B2 (en) * 1999-10-21 2011-05-17 Alcon, Inc. Drug delivery device
ES2315598T3 (es) 1999-10-21 2009-04-01 Alcon, Inc. Dispositivo para la administracion de farmacos.
DE60018777T2 (de) 1999-10-21 2006-02-02 Alcon Inc. Medikamentenversorgung der sub-tenon
US6416777B1 (en) * 1999-10-21 2002-07-09 Alcon Universal Ltd. Ophthalmic drug delivery device
US6267954B1 (en) * 1999-11-24 2001-07-31 Universite De Paris V Rene-Descartes Intraocular transplantation of encapsulated cells
JP2003522160A (ja) * 2000-02-11 2003-07-22 ジェンベク、インコーポレイティッド 眼関連疾患の治療のための遺伝子治療
WO2002017831A2 (en) * 2000-08-30 2002-03-07 John Hopkins University Devices for intraocular drug delivery
US6697668B2 (en) * 2001-01-25 2004-02-24 Iomed, Inc. Ocular iontophoretic device and method for using the same
US6546284B2 (en) * 2001-01-25 2003-04-08 Iomed, Inc. Fluid retention assembly for an iontophoretic delivery device and associated method for preparing the same
US7181287B2 (en) * 2001-02-13 2007-02-20 Second Sight Medical Products, Inc. Implantable drug delivery device
US6875165B2 (en) 2001-02-22 2005-04-05 Retinalabs, Inc. Method of radiation delivery to the eye
EP1387671A1 (de) 2001-05-03 2004-02-11 MASSACHUSETTS EYE & EAR INFIRMARY Implantierbare arzneistoffverabreichungsvorrichtung und verwendung derselben
EP2316394B1 (de) 2001-06-12 2016-11-23 The Johns Hopkins University Reservoirvorrichtung für die intraokulare Arzneimittelabgabe
US7031776B2 (en) 2001-06-29 2006-04-18 Optobionics Methods for improving damaged retinal cell function
US20050033202A1 (en) * 2001-06-29 2005-02-10 Chow Alan Y. Mechanically activated objects for treatment of degenerative retinal disease
DE10133870A1 (de) * 2001-07-12 2003-02-06 Chris P Lohmann Ophthalmisches Mittel, Verwendung von EGF zur Behandlung von Dry Eye-Syndrom und Insert zur Verabreichung von EGF am Auge
EP1385452B1 (de) * 2001-07-23 2006-09-13 Alcon, Inc. Vorrichtung zur freisetzung eines ophthalmischen arzneimittels
ES2278936T3 (es) 2001-07-23 2007-08-16 Alcon, Inc. Dispositivo de administracion de farmacos oftalmicos.
KR20040028966A (ko) 2001-08-01 2004-04-03 메르크 파텐트 게엠베하 안구 질환 치료용 인테그린 억제제
AU2003217531A1 (en) * 2002-05-02 2003-11-17 Massachusetts Eye And Ear Infirmary Ocular drug delivery systems and use thereof
AU2003279055A1 (en) * 2002-09-29 2004-04-19 Surmodics, Inc. Methods for treatment and/or prevention of retinal disease
WO2004073551A2 (en) * 2003-02-18 2004-09-02 Massachusetts Eye And Ear Infirmary Transscleral drug delivery device and related methods
US8246974B2 (en) * 2003-05-02 2012-08-21 Surmodics, Inc. Medical devices and methods for producing the same
WO2004098565A2 (en) * 2003-05-02 2004-11-18 Surmodics, Inc. Implantable controlled release bioactive agent delivery device
ATE423134T1 (de) 2003-06-10 2009-03-15 Nsgene As Verbesserte sezernierung von neublastin
MXPA05011517A (es) * 2003-07-10 2005-12-12 Alcon Inc Dispositivo para el suministro de medicamentos oftalmicos.
CN102144961A (zh) * 2003-09-18 2011-08-10 参天制药株式会社 经巩膜递送
ATE460183T1 (de) 2003-10-20 2010-03-15 Nsgene As Viraler vektor zur verwendung in der in-vivo- gentherapie von morbus parkinson
US20050136095A1 (en) * 2003-12-22 2005-06-23 Brian Levy Drug delivery device with suture ring
IL159818A0 (en) * 2004-01-12 2004-06-20 Nulens Ltd Intraocular structure
AU2005214040B2 (en) * 2004-02-12 2011-03-31 Neo Vista, Inc. Methods and apparatus for intraocular brachytherapy
US7563222B2 (en) * 2004-02-12 2009-07-21 Neovista, Inc. Methods and apparatus for intraocular brachytherapy
CA2561577A1 (en) 2004-03-30 2005-10-13 Nsgene A/S Therapeutic use of a growth factor, nsg33
WO2006002366A2 (en) * 2004-06-24 2006-01-05 Surmodics, Inc. Biodegradable ocular devices, methods and systems
US20060110428A1 (en) 2004-07-02 2006-05-25 Eugene Dejuan Methods and devices for the treatment of ocular conditions
WO2006013462A2 (en) * 2004-07-30 2006-02-09 Nsgene A/S Growth factors nsg28, nsg30, and nsg32
US20060034891A1 (en) * 2004-08-12 2006-02-16 Laurie Lawin Biodegradable controlled release bioactive agent delivery device
US8246569B1 (en) 2004-08-17 2012-08-21 California Institute Of Technology Implantable intraocular pressure drain
BRPI0517551A (pt) * 2004-10-04 2008-10-14 Cellgate Inc análogos de poliamina como agentes terapêuticos para doenças oculares
US8663639B2 (en) * 2005-02-09 2014-03-04 Santen Pharmaceutical Co., Ltd. Formulations for treating ocular diseases and conditions
CA2597590A1 (en) 2005-02-09 2006-08-17 Macusight, Inc. Formulations for ocular treatment
TW200640443A (en) * 2005-02-23 2006-12-01 Alcon Inc Methods for treating ocular angiogenesis, retinal edema, retinal ischemia, and diabetic retinopathy using selective RTK inhibitors
US20060233858A1 (en) * 2005-03-08 2006-10-19 Allergan, Inc. Systems and methods providing targeted intraocular drug delivery
US20070077270A1 (en) * 2005-03-28 2007-04-05 Clemson University Delivery devices and methods for long-term, targeted delivery of therapeutic agents to the eye and ear
US8088567B2 (en) 2005-04-01 2012-01-03 Nsgene A/S Human immortalised neural precursor cell line
EP1868661A1 (de) * 2005-04-08 2007-12-26 SurModics, Inc. Implantate mit verzögerter freisetzung zur subretinalen verabreichung
US20060258994A1 (en) * 2005-05-12 2006-11-16 Avery Robert L Implantable delivery device for administering pharmacological agents to an internal portion of a body
NZ563313A (en) * 2005-05-17 2010-01-29 Nsgene As An implantable therapy system for treating a living being with an active factor
US8309057B2 (en) 2005-06-10 2012-11-13 The Invention Science Fund I, Llc Methods for elevating neurotrophic agents
JP2009502954A (ja) 2005-07-27 2009-01-29 ユニバーシティ オブ フロリダ リサーチ ファウンデーション，インコーポレイティド タンパク質のミスフォールディングを修正する小分子及びその使用
CA2629648A1 (en) 2005-11-15 2007-05-24 Neovista Inc. Methods and apparatus for intraocular brachytherapy
JP5180834B2 (ja) 2005-11-29 2013-04-10 スミスクライン ビーチャム コーポレーション 治療方法
ES2406716T3 (es) * 2005-12-30 2013-06-07 Neurotech Usa, Inc. Dispositivo micronizado para el suministro de moléculas activas biológicamente y método de uso del mismo
CA2636068A1 (en) * 2006-01-17 2007-07-26 Nulens Ltd Intraocular drug dispenser
BRPI0707612B8 (pt) 2006-02-09 2021-05-25 Macusight Inc vaso lacrado e formulações líquidas contidas no mesmo
DE602007012417D1 (de) * 2006-03-14 2011-03-24 Univ Southern California Mems-Vorrichtung zur Wirkstofffreisetzung
WO2007112052A2 (en) * 2006-03-23 2007-10-04 Macusight, Inc. Formulations and methods for vascular permeability-related diseases or conditions
MX2009006146A (es) * 2006-12-18 2009-06-19 Alcon Res Ltd Dispositivos y metodos para la administracion de farmacos oftalmicos.
US20080265343A1 (en) * 2007-04-26 2008-10-30 International Business Machines Corporation Field effect transistor with inverted t shaped gate electrode and methods for fabrication thereof
JP5542691B2 (ja) * 2007-12-20 2014-07-09 ユニバーシティ オブ サザン カリフォルニア 治療薬を送達するための装置および方法
JP2011509120A (ja) 2008-01-03 2011-03-24 ユニバーシティ オブ サザン カリフォルニア 埋め込み可能な薬物送達デバイス、及び当該デバイスを補充するための装置および方法
CN103394142B (zh) 2008-05-08 2015-08-19 迷你泵有限责任公司 可植入药物传送装置与用于填充该装置的设备和方法
JP5719767B2 (ja) * 2008-05-08 2015-05-20 ミニパンプス， エルエルシー 埋込型ポンプおよびそのためのカニューレ
EP2323716B1 (de) 2008-05-08 2015-03-04 MiniPumps, LLC Arzneiabgabepumpen
US9333297B2 (en) 2008-05-08 2016-05-10 Minipumps, Llc Drug-delivery pump with intelligent control
JP2011522603A (ja) 2008-06-04 2011-08-04 ネオビスタ、インコーポレイテッド 放射線源ワイヤを前進させるための手持ち放射線送達システム
WO2010083842A2 (en) 2009-01-23 2010-07-29 Nsgene A/S Expression of neuropeptides in mammalian cells
WO2010083841A2 (en) 2009-01-23 2010-07-29 Nsgene A/S Improved cell lines and their use in encapsulated cell biodelivery
US8632511B2 (en) * 2009-05-06 2014-01-21 Alcon Research, Ltd. Multiple thermal sensors in a multiple processor environment for temperature control in a drug delivery device
IN2012DN00352A (de) 2009-06-16 2015-08-21 Bikam Pharmaceuticals Inc
JP5758388B2 (ja) 2009-08-18 2015-08-05 ミニパンプス， エルエルシー 適応制御を有する電解質薬物送達ポンプ
US20120232102A1 (en) 2009-09-30 2012-09-13 Chun-Fang Xu Methods Of Administration And Treatment
US8177747B2 (en) * 2009-12-22 2012-05-15 Alcon Research, Ltd. Method and apparatus for drug delivery
WO2012041320A1 (en) 2010-09-27 2012-04-05 Nsgene A/S Implantable cell device with supportive and radial diffusive scaffolding
CN103269708A (zh) 2010-10-01 2013-08-28 Ns基因公司 镍纹蛋白用于治疗异常性疼痛、痛觉过敏、自发性疼痛和幻痛的用途
US9919099B2 (en) 2011-03-14 2018-03-20 Minipumps, Llc Implantable drug pumps and refill devices therefor
US10286146B2 (en) 2011-03-14 2019-05-14 Minipumps, Llc Implantable drug pumps and refill devices therefor
US9603997B2 (en) 2011-03-14 2017-03-28 Minipumps, Llc Implantable drug pumps and refill devices therefor
CA2838974A1 (en) 2011-06-14 2012-12-20 Bikam Pharmaceuticals, Inc. Opsin-binding ligands, compositions and methods of use
JP6145667B2 (ja) 2011-09-05 2017-06-14 ホーバ セラピューティクス アンパルトセルスカブ アロディニア、痛覚過敏、自発痛、及び幻痛の治療
WO2013058809A1 (en) 2011-10-19 2013-04-25 Bikam Pharmaceuticals, Inc. Opsin-binding ligands, compositions and methods of use
WO2013082000A1 (en) 2011-11-30 2013-06-06 Bikam Pharmaceuticals, Inc. Opsin-binding ligands, compositions and methods of use
WO2013081642A1 (en) 2011-12-01 2013-06-06 Bikam Pharmaceuticals, Inc. Opsin-binding ligands, compositions and methods of use
RU2494711C1 (ru) * 2012-05-18 2013-10-10 Федеральное государственное бюджетное учреждение "Межотраслевой научно-технический комплекс "Микрохирургия глаза" имени академика С.Н. Федорова" Министерства здравоохранения и социального развития Российской Федерации Способ хирургического лечения прогрессирующей и осложненной миопии
CA2874824C (en) 2012-06-01 2021-10-26 Surmodics, Inc. Apparatus and methods for coating balloon catheters
US9827401B2 (en) 2012-06-01 2017-11-28 Surmodics, Inc. Apparatus and methods for coating medical devices
US11090468B2 (en) 2012-10-25 2021-08-17 Surmodics, Inc. Apparatus and methods for coating medical devices
EP4302736A3 (de) 2013-03-28 2024-04-03 ForSight Vision4, Inc. Ophthalmisches implantat zur abgabe von therapeutischen substanzen
ES2950987T3 (es) 2013-09-11 2023-10-17 Neurotech Usa Inc Cartucho para terapia con células encapsuladas
CN114587774B (zh) 2014-11-10 2024-07-19 弗赛特影像4股份有限公司 治疗眼睛的系统
AU2017246889B2 (en) 2016-04-05 2021-12-16 Forsight Vision4, Inc. Implantable ocular drug delivery devices
WO2020112816A1 (en) 2018-11-29 2020-06-04 Surmodics, Inc. Apparatus and methods for coating medical devices
US11819590B2 (en) 2019-05-13 2023-11-21 Surmodics, Inc. Apparatus and methods for coating medical devices
JP2022553849A (ja) * 2019-11-01 2022-12-26 ニューロテック ユーエスエー，インコーポレイティド 埋め込み可能な検体拡散の機器のためのシステム、装置、機器及び方法

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5116798A (ja) * 1974-08-01 1976-02-10 Mihairoichi Kurasunofu Mihairu Jinkosuishotai
US5266562A (en) * 1987-11-19 1993-11-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Anti-inflammatory agents
US5521215A (en) * 1989-11-07 1996-05-28 Ramot University Authority For Applied Research And Industrial Development Ltd. NMDA-blocking pharmaceuticals
US5378475A (en) * 1991-02-21 1995-01-03 University Of Kentucky Research Foundation Sustained release drug delivery devices
US5382514A (en) * 1992-03-31 1995-01-17 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services In vivo angiogenesis assay
US5178635A (en) * 1992-05-04 1993-01-12 Allergan, Inc. Method for determining amount of medication in an implantable device
US5279298A (en) * 1992-11-20 1994-01-18 The Johns Hopkins University Method and apparatus to identify and treat neovascular membranes in the eye
US5443505A (en) * 1993-11-15 1995-08-22 Oculex Pharmaceuticals, Inc. Biocompatible ocular implants
US5550050A (en) * 1994-04-15 1996-08-27 Cytotherapeutics, Inc. Method for implanting encapsulated cells in a host
US5466233A (en) * 1994-04-25 1995-11-14 Escalon Ophthalmics, Inc. Tack for intraocular drug delivery and method for inserting and removing same
US5472436A (en) * 1994-07-26 1995-12-05 Fremstad; Daria A. Ocular appliance for delivering medication

Also Published As

Publication number Publication date
DK0927024T3 (da) 2005-08-29
DK1574209T3 (da) 2010-05-31
EP1574209A1 (de) 2005-09-14
AU716400B2 (en) 2000-02-24
CA2264895A1 (en) 1997-09-25
ATE296087T1 (de) 2005-06-15
ATE459335T1 (de) 2010-03-15
JP4740077B2 (ja) 2011-08-03
EP0927024B8 (de) 2005-08-31
JP2006342185A (ja) 2006-12-21
JP2010265314A (ja) 2010-11-25
ES2342075T3 (es) 2010-07-01
EP0927024A2 (de) 1999-07-07
EP0927024B1 (de) 2005-05-25
CA2264895C (en) 2008-05-27
WO1997034586A2 (en) 1997-09-25
JP2000507854A (ja) 2000-06-27
WO1997034586A3 (en) 1997-10-23
ES2242223T3 (es) 2005-11-01
EP1574209B1 (de) 2010-03-03
US5904144A (en) 1999-05-18
DE69733357D1 (de) 2005-06-30
DE69733357T2 (de) 2006-02-02
AU2541997A (en) 1997-10-10

Similar Documents

Publication Publication Date Title
DE69739792D1 (de) Verfahren zur Behandlung von Augenerkrankungen
ATE229806T1 (de) Wirkstoff zur behandlung neurodegenerativer störungen
ATE207352T1 (de) Nicht-allosterische gaba a agonisten zur behandlung von schlafstörungen
LV10262A (lv) Farmaceitisko savienojumu iegusanas metode
DE69725484D1 (de) Vorrichtung zur Behandlung von Harninkontinenz
ATE230757T1 (de) Verabreichung von peptidylheterocyclen zur behandlung von thrombin in zusammenhang stehenden krankheiten
ATE213411T1 (de) Verwendung von phenserin zur herstellung von medikamenten zur behandlung von kognitiven störungen
ATE137965T1 (de) Verwendung von tomoxetine zur behandlung von funktionsstörungen der niedrigen harnwege
ATE148628T1 (de) 5-methylisoxazol-4-carbonsäure-anilide und 2- hydroxyethyliden-cyanoessigsäure-anilide zur behandlung von augenkrankheiten
DK0894136T3 (da) Fremgangsmåde til behandling af muskulære lidelser
ATE222491T1 (de) Melatonin-derivate zur verwendung in der behandlung von schlafstörungen
ATE239470T1 (de) Melatonin-derivate zur verwendung in der behandlung von desynchronisierungs-erkankungen
DE69735417D1 (de) 2,5-dihydroxybenzylsulfonderivate zur behandlung von sexuellen störungen
DE69833727D1 (de) Verfahren zur Behandlung der Gefässerkrankungen mit aktiviertem Protein C
ATE295731T1 (de) Olanzapine zur behandlung von drogenmissbrauch
DE3585312D1 (de) Anwendung von 1,6-dimethyl-4-oxo-1,6,7,8,9a-hexahydro-4h-pyrido(1,2-a)pyrimidin-3-carboxamid zur vorbeugung und behandlung von gastrointestinalschaeden.
DE69800906D1 (de) Verwendung von Olanzapine zur Herstellung eines Arzneimittels zur Behandlung der zerebralen fokalen Ischämie
DE69830811D1 (de) Verwendung von Oxazolidinonderivaten zur Behandlung von Psoriasis
DE59404213D1 (de) Trainingsgerät zur Behandlung von an Wahrnehmungsstörungen leidenden Patienten
RU93046305A (ru) Способ лечения заболеваний глаз
UA12890A (uk) Спосіб акупуhктури
IT8919216A0 (it) Dispositivo per la cura chirurgica dell'astigmatismo.
RU94011848A (ru) Способ лечения хронического алкоголизма и/или наркомании

Legal Events

Date Code Title Description
8364 No opposition during term of opposition